Sanjiv J Shah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5103296/publications.pdf

Version: 2024-02-01

451	33,085	4658	5679
papers	citations	85 h-index	162 g-index

461	461	461	24773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Preoperative left atrial strain abnormalities are associated with the development of postoperative atrial fibrillation following isolated coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 917-924.	0.8	15
2	Adverse cardiac mechanics and incident coronary heart disease in the Cardiovascular Health Study. Heart, 2022, 108, 529-535.	2.9	6
3	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
4	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	2.9	3
5	Insulin Resistance Is Associated with Right Ventricular Dysfunction. Annals of the American Thoracic Society, 2022, 19, 562-571.	3.2	0
6	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
7	Association of Pericardial Fat with Cardiac Structure, Function, and Mechanics: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Society of Echocardiography, 2022, 35, 579-587.e5.	2.8	2
8	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	2.9	81
9	Collagen homeostasis of the left atrium: an emerging treatment target to prevent heart failure?. European Journal of Heart Failure, 2022, 24, 332-334.	7.1	2
10	Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 681-684.	7.1	16
11	Development and Validation of a Long-Term Incident Heart Failure Risk Model. Circulation Research, 2022, 130, 200-209.	4.5	9
12	Relation of Cigarette Smoking and Heart Failure in Adults â‰¥65ÂYears of Age (From the Cardiovascular) Tj ETQq0 0 0 rgBT /Overlock	1.6	6
13	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008193.	3.9	65
14	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and HeartÂFailure Risk in Black Adults. JACC: Heart Failure, 2022, 10, 129-138.	4.1	9
15	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Overloc	13.7	112
16	Genetic variation in sodium glucose coâ€transporter 1 and cardiac structure and function at middle age. ESC Heart Failure, 2022, 9, 1496-1501.	3.1	1
17	Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 804788.	2.4	6
18	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation, 2022, 145, 1592-1604.	1.6	54

#	Article	IF	Citations
19	BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. European Heart Journal, 2022, 43, 1952-1954.	2.2	20
20	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
21	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	4.1	75
22	Inclusion Criteria for HFpEF Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity. Journal of Cardiac Failure, 2022, , .	1.7	2
23	Atrial Fibrillation in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	4.1	18
24	Left atrial strain is associated with adverse cardiovascular events in patients with endâ€stage renal disease: Findings from the Cardiac, Endothelial Function and Arterial Stiffness in <scp>ESRD</scp> (<scp>CERES</scp>) study. Hemodialysis International, 2022, 26, 323-334.	0.9	8
25	Distribution of 10- and 30-Year Predicted Risks for Heart Failure in the US Population: National Health and Nutrition Examination Surveys 2015 to 2018. Circulation: Heart Failure, 2022, , CIRCHEARTFAILURE121009351.	3.9	1
26	Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 287-300.	2.1	9
27	Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. European Heart Journal, 2022, 43, 2196-2208.	2.2	12
28	Venous Tone and Stressed Blood Volume in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1858-1869.	2.8	35
29	Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease. Circulation Research, 2022, 130, 1382-1403.	4.5	13
30	Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the <scp>REBALANCEâ€HF</scp> trial rollâ€in cohort. European Journal of Heart Failure, 2022, 24, 1410-1414.	7.1	27
31	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	22
32	Glucose dysregulation and subclinical cardiac dysfunction in older adults: The Cardiovascular Health Study. Cardiovascular Diabetology, 2022, 21, .	6.8	3
33	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 2022, 21, .	6.8	14
34	The future of heart failure with preserved ejection fraction. Herz, 2022, 47, 308-323.	1.1	12
35	Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transplantation, 2021, 56, 50-59.	2.4	25
36	Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 309-317.	1.7	9

#	Article	IF	Citations
37	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	1.7	6
38	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2021, 69, 1309-1318.	2.6	4
39	Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021, 11, 430.	3.3	50
40	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	3.1	16
41	Risk-Based Approach for the Prediction and Prevention of Heart Failure. Circulation: Heart Failure, 2021, 14, e007761.	3.9	19
42	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 546-556.	2.7	26
43	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	7.1	12
44	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. Circulation: Heart Failure, 2021, 14, e008090.	3.9	5
45	Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. ESC Heart Failure, 2021, 8, 2089-2102.	3.1	21
46	Misfolded Transthyretin as a Novel Risk Factor for Heart Failure. JAMA Cardiology, 2021, 6, 255.	6.1	1
47	Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes. Journal of the American Heart Association, 2021, 10, e019519.	3.7	8
48	Spironolactone in Patients With HeartÂFailure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	2.8	19
49	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. Scientific Reports, 2021, 11, 4885.	3.3	31
50	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 754-764.	7.1	19
51	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
52	Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ, The, 2021, 372, n461.	6.0	83
53	Heart Failure Risk Distribution and Trends in the United States Population, NHANES 1999-2016. American Journal of Medicine, 2021, 134, e153-e164.	1.5	16
54	Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA). Biomarkers, 2021, 26, 309-317.	1.9	3

#	Article	IF	Citations
55	Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets. Current Heart Failure Reports, 2021, 18, 85-98.	3.3	19
56	Role of t-tubule remodeling on mechanisms of abnormal calcium release during heart failure development in canine ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1658-H1669.	3.2	6
57	Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2021, 34, 455-464.	2.8	5
58	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. Journal of Cardiac Failure, 2021, 27, 1214-1221.	1.7	0
59	Burden of HeartÂFailure Signs and Symptoms, Prognosis, and ResponseÂtoÂTherapy. JACC: Heart Failure, 2021, 9, 386-397.	4.1	11
60	Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF. JACC: Heart Failure, 2021, 9, 360-370.	4.1	42
61	A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nature Communications, 2021, 12, 2725.	12.8	56
62	Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nature Communications, 2021, 12, 2726.	12.8	73
63	Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2535-2545.	3.1	21
64	Association Between Myocardial Strain and Frailty in CHS. Circulation: Cardiovascular Imaging, 2021, 14, e012116.	2.6	5
65	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	7.1	195
66	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	5.6	68
67	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults. JAMA Cardiology, 2021, 6, 718.	6.1	7
68	Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension, 2021, 77, 2023-2033.	2.7	4
69	Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis. JCI Insight, 2021, 6, .	5.0	4
70	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
71	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1. JAMA Cardiology, 2021, 6, 841.	6.1	8
72	Associations of Cardiac Mechanics With Exercise Capacity. Journal of the American College of Cardiology, 2021, 78, 245-257.	2.8	13

#	Article	IF	Citations
73	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
74	Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 1541-1551.	7.1	12
75	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	1.7	0
76	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
77	The splanchnic reservoir: an oasis for blood volume in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2021, 23, 1144-1146.	7.1	1
78	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. Journal of Cardiac Failure, 2021, 27, 756-765.	1.7	20
79	Transmethylamineâ€Nâ€Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Journal of the American Heart Association, 2021, 10, e020499.	3.7	7
80	Associations of body size and composition with subclinical cardiac dysfunction in older individuals: the cardiovascular health study. International Journal of Obesity, 2021, 45, 2539-2545.	3.4	5
81	Cardiac mechanics and incident ischemic stroke: the Cardiovascular Health Study. Scientific Reports, 2021, 11, 17358.	3.3	12
82	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3495-3503.	3.1	3
83	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019545.	3.7	29
84	Exercise Intolerance in Older Adults WithÂHeartÂFailure With Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 1166-1187.	2.8	87
85	Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial. Journal of Cardiac Failure, 2021, 27, 1023-1026.	1.7	11
86	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	3.9	25
87	Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis. JACC: Heart Failure, 2021, 9, 795-802.	4.1	17
88	Risk Markers for Limited Coronary Artery Calcium in Persons With Significant Aortic Valve Calcium (From the Multi-ethnic Study of Atherosclerosis). American Journal of Cardiology, 2021, 156, 58-64.	1.6	7
89	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
90	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008293.	3.9	18

#	Article	IF	Citations
91	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	30.7	299
92	Risk-Based Intensive Blood Pressure Lowering and Prevention of Heart Failure: A SPRINT Post Hoc Analysis. Hypertension, 2021, 78, 1742-1749.	2.7	7
93	Risk Marker Fatigueâ€"Is There an Actionable Outcome?. JAMA Cardiology, 2021, 6, 78.	6.1	0
94	The association between indices of blood pressure waveforms (PTC1 and PTC2) and incident heart failure. Journal of Hypertension, 2021, 39, 661-666.	0.5	4
95	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	7.4	72
96	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Frontiers in Cardiovascular Medicine, 2021, 8, 785109.	2.4	1
97	SNPs Filtered by Allele Frequency Improve the Prediction of Hypertension Subtypes. , 2021, , .		0
98	Association of liver stiffness and cardiovascular outcomes in patients with heart failure: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 331-334.	1.8	10
99	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 101-107.	1.7	26
100	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
101	Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life. JAMA Cardiology, 2020, 5, 184.	6.1	18
102	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal of Cardiac Failure, 2020, 26, 371-380.	1.7	25
103	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2020, 22, 557-559.	7.1	5
104	Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1647-1653.	1.2	20
105	Validation of the HFAâ€PEFF score for the diagnosis of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 413-421.	7.1	101
106	Polygenic Risk, Fitness, and Obesity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Cardiology, 2020, 5, 263.	6.1	15
107	Left atrial function in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2020, 22, 472-485.	7.1	71
108	Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Failure, 2020, 7, 254-264.	3.1	39

#	Article	IF	Citations
109	Associations of awake and asleep blood pressure and blood pressure dipping with abnormalities of cardiac structure. Journal of Hypertension, 2020, 38, 102-110.	0.5	14
110	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275.	1.7	10
111	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
112	Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II). American Heart Journal, 2020, 226, 222-231.	2.7	32
113	COVID-19 and Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1499.	7.4	71
114	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	7.4	170
115	Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1522.	7.4	79
116	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€•. Circulation, 2020, 142, e212-e213.	1.6	1
117	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. Circulation: Heart Failure, 2020, 13, e007462.	3.9	17
118	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 2029-2044.	1.6	117
119	Relation of Biomarkers of Cardiac Injury, Stress, and Fibrosis With Cardiac Mechanics in Patients â‰¥ 65 Years of Age. American Journal of Cardiology, 2020, 136, 156-163.	1.6	6
120	Endomyocardial Biopsy Characterization of HeartÂFailure With Preserved EjectionÂFraction and Prevalence of Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 712-724.	4.1	138
121	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. Digital Biomarkers, 2020, 4, 45-59.	4.4	8
122	Circulating Vascular Cell Adhesion Moleculeâ€1 and Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2020, 9, e019390.	3.7	30
123	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology, 2020, 76, 503-514.	2.8	77
124	Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 919-928.	1.7	10
125	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. Journal of Cardiac Failure, 2020, 26, 1016-1021.	1.7	29
126	The Upcoming Epidemic of Heart Failure in South Asia. Circulation: Heart Failure, 2020, 13, e007218.	3.9	37

#	Article	IF	Citations
127	Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1455-1465.	2.8	54
128	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e016760.	3.7	19
129	Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure. Heart Failure Clinics, 2020, 16, 387-407.	2.1	19
130	Genetic-Based Hypertension Subtype Identification Using Informative SNPs. Genes, 2020, 11, 1265.	2.4	5
131	Fibroblast Growth Factor 23 and Long-Term Cardiac Function. Circulation: Cardiovascular Imaging, 2020, 13, e011925.	2.6	21
132	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. ESC Heart Failure, 2020, 7, 1676-1687.	3.1	9
133	Myocardial Infarction in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 618-626.	4.1	17
134	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. Circulation, 2020, 142, 230-243.	1.6	59
135	Cellular Adhesion Molecules in YoungÂAdulthood and Cardiac Function in LaterÂLife. Journal of the American College of Cardiology, 2020, 75, 2156-2165.	2.8	33
136	Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. European Journal of Heart Failure, 2020, 22, 1009-1018.	7.1	111
137	Variation in clinical and patientâ€reported outcomes among complex heart failure with preserved ejection fraction phenotypes. ESC Heart Failure, 2020, 7, 811-824.	3.1	11
138	Research Priorities for Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 141, 1001-1026.	1.6	239
139	Evaluation of highâ€sensitivity Câ€reactive protein and uric acid in vericiguatâ€treated patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1675-1683.	7.1	24
140	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	4.1	53
141	Therapeutic Targeting of Left Atrial Myopathy in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2020, 5, 497.	6.1	38
142	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. ESC Heart Failure, 2020, 7, 1956-1965.	3.1	43
143	Embarking upon atrial fibrillation management in heart failure with preserved ejection fraction: Charting a course. Journal of Cardiovascular Electrophysiology, 2020, 31, 2284-2287.	1.7	1
144	Coronary Microvascular Dysfunction in HIV: A Review. Journal of the American Heart Association, 2020, 9, e014018.	3.7	16

#	Article	IF	Citations
145	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147
146	Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart, 2020, 106, 342-349.	2.9	89
147	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). American Heart Journal, 2020, 222, 183-190.	2.7	14
148	Heart Failure With Preserved Ejection Fraction and Obesity. JACC: Case Reports, 2020, 2, 28-32.	0.6	2
149	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 233-242.	1.7	9
150	Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study. Journal of the American Heart Association, 2020, 9, e013966.	3.7	14
151	Differential Associations of ChronicÂInflammatory Diseases With Incident HeartÂFailure. JACC: Heart Failure, 2020, 8, 489-498.	4.1	39
152	Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure, 2020, 7, 856-864.	3.1	33
153	Longitudinal Association of Nonâ€Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. Journal of the American Heart Association, 2020, 9, e014279.	3.7	72
154	Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study. JCI Insight, 2020, 5, .	5.0	22
155	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. PLoS ONE, 2020, 15, e0240567.	2.5	4
156	Association of the H₂FPEF Risk Score with Recurrence of Atrial Fibrillation Following Pulmonary Vein Isolation. Journal of Atrial Fibrillation, 2020, 12, 2295.	0.5	4
157	Title is missing!. , 2020, 15, e0240567.		0
158	Title is missing!. , 2020, 15, e0240567.		0
159	Title is missing!. , 2020, 15, e0240567.		0
160	Title is missing!. , 2020, 15, e0240567.		0
161	Clinical correlates and heritability of cardiac mechanics: The HyperGEN study. International Journal of Cardiology, 2019, 274, 208-213.	1.7	5
162	Genomeâ€wide metaâ€analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans. Molecular Genetics & Genomic Medicine, 2019, 7, e00788.	1.2	4

#	Article	IF	Citations
163	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	2.8	170
164	Impact of Malnutrition Using Geriatric Nutritional Risk Index in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 664-675.	4.1	68
165	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clinic Proceedings, 2019, 94, 1199-1209.	3.0	68
166	Application of the H₂FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 1288-1291.	7.1	18
167	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 140, 1359-1361.	1.6	16
168	Association of Lipidomic Profiles With Progression of Carotid Artery Atherosclerosis in HIV Infection. JAMA Cardiology, 2019, 4, 1239.	6.1	26
169	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	1.6	13
170	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicineâ€"Digital Biopsy to Deconstruct Biology. Journal of the American Society of Echocardiography, 2019, 32, 1379-1395.e2.	2.8	15
171	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
172	Ankleâ€"brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis. Vascular Medicine, 2019, 24, 501-510.	1.5	8
173	Angiotensinâ€"Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
174	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
175	Coronary Microvascular Dysfunction and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 843-845.	1.7	14
176	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
177	Prevalence of American Heart Association Heart Failure Stages in Black and White Young and Middle-Aged Adults. Circulation: Heart Failure, 2019, 12, e005730.	3.9	19
178	Parent-of-origin effects on quantitative phenotypes in a large Hutterite pedigree. Communications Biology, 2019, 2, 28.	4.4	20
179	Targeted Therapeutics for Transthyretin Cardiac Amyloidosis. Circulation, 2019, 139, 444-447.	1.6	7
180	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. Trends in Molecular Medicine, 2019, 25, 328-340.	6.7	51

#	Article	IF	Citations
181	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006125.	3.9	21
182	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	3.9	33
183	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101.	7.4	47
184	10-Year Risk Equations for Incident HeartÂFailure in the General Population. Journal of the American College of Cardiology, 2019, 73, 2388-2397.	2.8	107
185	Long-Term Cardiovascular Risks Associated With AdverseÂPregnancyÂOutcomes. Journal of the American College of Cardiology, 2019, 73, 2106-2116.	2.8	156
186	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	4.1	33
187	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 20.	0.9	30
188	Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Ratesâ€"Reply. JAMA Cardiology, 2019, 4, 299.	6.1	1
189	Elevated Plasma Ceramides Are Associated With Antiretroviral Therapy Use and Progression of Carotid Artery Atherosclerosis in HIV Infection. Circulation, 2019, 139, 2003-2011.	1.6	30
190	Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 1680-1682.	1.8	8
191	Myocardial Strain in the Assessment of Patients With Heart Failure. JAMA Cardiology, 2019, 4, 287.	6.1	82
192	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). American Journal of Cardiology, 2019, 123, 1660-1666.	1.6	5
193	Effects of Interatrial Shunt on Pulmonary Vascular Function in HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2539-2550.	2.8	69
194	Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA. Journal of the American Heart Association, 2019, 8, e013149.	3.7	17
195	The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. Current Opinion in Supportive and Palliative Care, 2019, 13, 24-30.	1.3	19
196	Echocardiographic Features of PatientsÂWith HeartÂFailure and PreservedÂLeft Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2858-2873.	2.8	138
197	Influence of Age on Efficacy and Safety ofÂSpironolactone in HeartÂFailure. JACC: Heart Failure, 2019, 7, 1022-1028.	4.1	6
198	Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection. Aids, 2019, 33, 1043-1052.	2.2	3

#	Article	IF	Citations
199	Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization. Bioinformatics, 2019, 35, 1395-1403.	4.1	12
200	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂDisease. JACC: Heart Failure, 2019, 7, 25-32.	4.1	51
201	Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans. Journal of Cardiac Failure, 2019, 25, 51-59.	1.7	13
202	History of Atrial Fibrillation and Trajectory of Decongestion in AcuteÂHeart Failure. JACC: Heart Failure, 2019, 7, 47-55.	4.1	10
203	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. Annual Review of Pharmacology and Toxicology, 2019, 59, 41-63.	9.4	23
204	Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis. American Journal of Hypertension, 2018, 31, 774-783.	2.0	22
205	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal of Cardiac Failure, 2018, 24, 255-265.	1.7	32
206	Sudden Death in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 653-661.	4.1	56
207	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. Circulation: Heart Failure, 2018, 11, e004312.	3.9	37
208	Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease. Circulation: Heart Failure, 2018, 11, e004436.	3.9	85
209	Plasma Tryptophan-Kynurenine Metabolites Are Altered in Human Immunodeficiency Virus Infection and Associated With Progression of Carotid Artery Atherosclerosis. Clinical Infectious Diseases, 2018, 67, 235-242.	5.8	52
210	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 215.	6.1	186
211	Teasing Apart Heart Failure With Preserved Ejection Fraction Phenotypes With Echocardiographic Imaging. Circulation Research, 2018, 122, 23-25.	4.5	13
212	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. Pulmonary Circulation, 2018, 8, 1-8.	1.7	10
213	Lack of Association Between HeartÂFailure and Incident Cancer. Journal of the American College of Cardiology, 2018, 71, 1501-1510.	2.8	49
214	Population-Based Studies of Invasive Hemodynamics. JAMA Cardiology, 2018, 3, 306.	6.1	0
215	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation: Heart Failure, 2018, 11, e004457.	3.9	31
216	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of Cardiac Failure, 2018, 24, 313-320.	1.7	49

#	Article	IF	Citations
217	Sex differences in vascular dysfunction and cardiovascular outcomes: The cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study. Hemodialysis International, 2018, 22, 93-102.	0.9	14
218	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
219	Influence of ejection fraction on causeâ€specific mortality in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 815-816.	7.1	5
220	Resting and exercise haemodynamics in relation to sixâ€minute walk test in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 715-722.	7.1	41
221	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	7.1	91
222	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]). Circulation, 2018, 137, 364-375.	1.6	206
223	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. European Journal of Heart Failure, 2018, 20, 483-490.	7.1	28
224	Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas, 2018, 108, 37-44.	2.4	64
225	Adjudicated Heart Failure in HIVâ€Infected and Uninfected Men and Women. Journal of the American Heart Association, 2018, 7, e009985.	3.7	68
226	Sex Hormones and Change in N-Terminal Proâ€“B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4304-4314.	3.6	34
227	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	7.4	187
228	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005288.	3.9	35
229	Fully Automated Echocardiogram Interpretation in Clinical Practice. Circulation, 2018, 138, 1623-1635.	1.6	563
230	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2018, 11, e004540.	3.9	23
231	New DEStiny Revealed. Circulation, 2018, 138, 1267-1271.	1.6	1
232	Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy. Journal of the American Heart Association, 2018, 7, e09841.	3.7	23
233	The Urgent Need for Biomarkers Beyond B-Type Natriuretic Peptide for the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1211.	6.1	5
234	Metaâ€Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009594.	3.7	87

#	Article	IF	Citations
235	Association of Patterns of Change in Adiposity With Diastolic Function and Systolic Myocardial Mechanics From Early Adulthood to Middle Age: The Coronary Artery Risk Development in Young Adults Study. Journal of the American Society of Echocardiography, 2018, 31, 1261-1269.e8.	2.8	13
236	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1â€receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610.	7.1	27
237	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	6.1	121
238	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1033-H1042.	3.2	101
239	Endogenous Sex Hormones and IncidentÂCardiovascular Disease in Post-Menopausal Women. Journal of the American College of Cardiology, 2018, 71, 2555-2566.	2.8	250
240	Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. Journal of Scleroderma and Related Disorders, 2018, 3, 159-169.	1.7	22
241	Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure, 2018, 6, 619-632.	4.1	103
242	A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure Rehospitalization. Journal of Cardiac Failure, 2018, 24, 614-617.	1.7	9
243	Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 122, 1359-1365.	1.6	6
244	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	3.9	117
245	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 689-697.	4.1	68
246	The Association of Obesity and Cardiometabolic Traits With IncidentÂHFpEF and HFrEF. JACC: Heart Failure, 2018, 6, 701-709.	4.1	254
247	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
248	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal, 2018, 39, 3439-3450.	2.2	375
249	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1000.	6.1	41
250	Gut Microbial-Related Choline Metabolite Trimethylamine-N-Oxide Is Associated With Progression of Carotid Artery Atherosclerosis in HIV Infection. Journal of Infectious Diseases, 2018, 218, 1474-1479.	4.0	34
251	Association of the von Willebrand Factorâ€“ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 807-813.	1.7	14
252	Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation. Stem Cell Research, 2017, 18, 41-44.	0.7	6

#	Article	IF	Citations
253	Generation of human iPSCs from urine derived cells of a non-affected control subject. Stem Cell Research, 2017, 18, 33-36.	0.7	6
254	Fine mapping of QT interval regions in global populations refines previously identified QT interval loci and identifies signals unique to African and Hispanic descent populations. Heart Rhythm, 2017, 14, 572-580.	0.7	19
255	Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	20
256	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opinion on Pharmacotherapy, 2017, 18, 399-409.	1.8	20
257	Mode of Death in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 69, 556-569.	2.8	193
258	Sedentary Lifestyle and the Risk for HFpEF. Journal of the American College of Cardiology, 2017, 69, 1143-1146.	2.8	7
259	Reduced haemodynamic coupling and exercise are associated with vascular stiffening in pulmonary arterial hypertension. Heart, 2017, 103, 421-427.	2.9	24
260	Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 275-284.	2.4	61
261	Association of Albuminuria With Cardiac Dysfunction in US Hispanics/Latinos. American Journal of Cardiology, 2017, 119, 2073-2080.	1.6	6
262	RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With PreservedÂEjectionÂFraction. JACC: Cardiovascular Imaging, 2017, 10, 1211-1221.	5.3	297
263	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€"Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	5.6	59
264	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.9	47
265	Prevalence and Predictors of Diastolic Dysfunction According to Different Classification Criteria. American Journal of Epidemiology, 2017, 185, 1221-1227.	3.4	21
266	Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. Vascular Medicine, 2017, 22, 218-224.	1.5	3
267	Rasmussen-Torvik et al. Respond to â€œThe Perfect Measure of Diastolic Dysfunctionâ€• American Journal of Epidemiology, 2017, 185, 1231-1232.	3.4	1
268	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq0 0 0 rgBT /Overlock 10	3.9	59
269	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease. Circulation: Heart Failure, 2017, 10, .	3.9	35
270	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.6	80

#	Article	IF	Citations
271	Patientâ€reported outcomes in the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE patientS</scp> with <scp>PRESERVED</scp> ejection fraction (<scp>SOCRATESâ€PRESERVED</scp>) study. European Journal of Heart Failure, 2017, 19, 782-791.	7.1	84
272	Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials. Journal of Cardiovascular Translational Research, 2017, 10, 313-321.	2.4	50
273	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. Journal of Cardiovascular Translational Research, 2017, 10, 233-244.	2.4	66
274	Differences in Repolarization Heterogeneity Among Heart Failure With Preserved Ejection Fraction Phenotypic Subgroups. American Journal of Cardiology, 2017, 120, 601-606.	1.6	15
275	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-Î² and Cardiac Fibrosis. Circulation, 2017, 136, 664-679.	1.6	64
276	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplantation, 2017, 52, 1495-1503.	2.4	88
277	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	2.2	285
278	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1043-1052.	7.1	34
279	Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 305-312.	2.4	34
280	Interaction Between Spironolactone and Natriuretic Peptides in Patients With HeartÂFailure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 241-252.	4.1	129
281	Reassessing Phase II Heart Failure Clinical Trials. Circulation: Heart Failure, 2017, 10, .	3.9	14
282	Stepping Out of the Left Ventricleâ€™s Shadow. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	36
283	A Test in Context. Journal of the American College of Cardiology, 2017, 69, 1451-1464.	2.8	240
284	Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Current Heart Failure Reports, 2017, 14, 519-528.	3.3	44
285	Clinical characteristics of HIV-infected patients with adjudicated heart failure. European Journal of Preventive Cardiology, 2017, 24, 1746-1758.	1.8	25
286	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	7.1	34
287	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 782-791.	4.1	21
288	The potential role and rationale for treatment of heart failure with sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	7.1	139

#	Article	IF	Citations
289	Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!. European Journal of Heart Failure, 2017, 19, 1516-1519.	7.1	2
290	Association of Estimated SodiumÂIntakeÂWith Adverse Cardiac Structure andÂFunction. Journal of the American College of Cardiology, 2017, 70, 715-724.	2.8	21
291	Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report. ESC Heart Failure, 2017, 4, 645-648.	3.1	8
292	A null mutation in SERPINE1 protects against biological aging in humans. Science Advances, 2017, 3, eaao1617.	10.3	95
293	Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2062-2068.	5.6	22
294	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Translational Research, 2017, 10, 322-336.	2.4	41
295	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Current Heart Failure Reports, 2017, 14, 217-222.	3.3	13
296	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. , 2017, 176, 32-39.		54
297	Albuminuria, kidney function, and sudden cardiac death: Findings from The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Heart Rhythm, 2017, 14, 65-71.	0.7	11
298	GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals. Scientific Reports, 2017, 7, 17075.	3.3	23
299	Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD. International Journal of COPD, 2017, Volume 12, 1439-1446.	2.3	13
300	Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. Journal of Clinical Investigation, 2017, 127, 1798-1812.	8.2	106
301	Cardiac Involvement: Evaluation and Management. , 2017, , 331-356.		0
302	Whole Exome Analyses to Examine the Impact of Rare Variants on Left Ventricular Traits in African American Participants from the HyperGEN and GENOA Studies. Journal of Hypertension and Management, 2017, 3, .	0.2	0
303	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
304	Repolarization Heterogeneity: Beyond the QT Interval. Journal of the American Heart Association, 2016, 5, .	3.7	52
305	The HFpEF Obesity Phenotype. Journal of the American College of Cardiology, 2016, 68, 200-203.	2.8	130
306	Pedal Edema as an Indicator of Early Heart Failure in the Community. Circulation: Heart Failure, 2016, 9, .	3.9	5

#	Article	IF	Citations
307	Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation. Stem Cell Research, 2016, 17, 657-660.	0.7	3
308	A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor?. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 1288-1299.	0.8	20
309	Integrated analyses of gene expression and genetic association studies in a founder population. Human Molecular Genetics, 2016, 25, 2104-2112.	2.9	18
310	Burden of Systolic and Diastolic Left Ventricular Dysfunction Among Hispanics in the United States. Circulation: Heart Failure, 2016, 9, e002733.	3.9	45
311	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002763.	3.9	224
312	Response to Letter Regarding Article, â€œEvaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrateâ€• Circulation, 2016, 133, e431.	1.6	0
313	Impact of the Gather mHealth System on A1C: Primary Results of a Multisite Randomized Clinical Trial Among People With Type 2 Diabetes in India. Diabetes Care, 2016, 39, e169-e170.	8.6	20
314	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. European Journal of Heart Failure, 2016, 18, 54-65.	7.1	73
315	Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 103-112.	7.1	140
316	Repolarization heterogeneity, diastolic dysfunction, and cardiovascular outcomes in heart failure with preserved ejection fraction. International Journal of Cardiology, 2016, 223, 116-117.	1.7	2
317	Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease. Hypertension, 2016, 68, 913-920.	2.7	28
318	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	51
319	Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	29
320	HIV-Related Myocardial Vulnerability to Infarction and Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 2026-2027.	2.8	20
321	Association of Central Adiposity With Adverse Cardiac Mechanics. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	65
322	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	46
323	How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program. Current Cardiology Reports, 2016, 18, 122.	2.9	27
324	Archeological Echocardiography: Digitization and Speckle Tracking Analysis of Archival Echocardiograms in the Hyper<scp>GEN</scp> Study. Echocardiography, 2016, 33, 386-397.	0.9	24

#	Article	IF	Citations
325	Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?. Current Heart Failure Reports, 2016, 13, 132-139.	3.3	11
326	MR and CT Imaging for the Evaluation ofÂPulmonary Hypertension. JACC: Cardiovascular Imaging, 2016, 9, 715-732.	5.3	72
327	Constitutive Expression of a Dominant-Negative TGF-Î² Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. Circulation Research, 2016, 119, 69-82.	4.5	44
328	Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Current Atherosclerosis Reports, 2016, 18, 48.	4.8	10
329	Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. Journal of Translational Medicine, 2016, 14, 18.	4.4	21
330	Predicting Heart Failure With Preserved and Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	227
331	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation, 2016, 134, 73-90.	1.6	747
332	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. Heart Failure Reviews, 2016, 21, 455-462.	3.9	26
333	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal, 2016, 37, 455-462.	2.2	396
334	Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	268
335	Inflammation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 325-328.	4.1	28
336	Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. Vascular Medicine, 2016, 21, 120-129.	1.5	21
337	Comparison of Echocardiographic Measures in a Hispanic/Latino Population With the 2005 and 2015 American Society of Echocardiography Reference Limits (The Echocardiographic Study of Latinos). Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	20
338	Reply. JACC: Heart Failure, 2016, 4, 93.	4.1	0
339	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Failure Reviews, 2016, 21, 285-297.	3.9	25
340	Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study. Vascular Medicine, 2016, 21, 12-20.	1.5	17
341	Interventional heart failure: a new field. EuroIntervention, 2016, 12, X85-X88.	3.2	9
342	Effects of Ranolazine on Exercise Capacity, Right Ventricular Indices, and Hemodynamic Characteristics in Pulmonary Arterial Hypertension: A Pilot Study. Pulmonary Circulation, 2015, 5, 547-556.	1.7	56

#	Article	IF	Citations
343	Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: Results from two institutions. Magnetic Resonance in Medicine, 2015, 73, 1904-1913.	3.0	116
344	Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A populationâ€based study. Hepatology, 2015, 62, 773-783.	7.3	221
345	Constrictive Pericarditis as a Cause of Refractory Ascites. ACG Case Reports Journal, 2015, 2, 175-177.	0.4	5
346	Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 76-85.	5.6	54
347	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation, 2015, 131, 34-42.	1.6	758
348	Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2015, 31, 430-439.	1.7	31
349	Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial. Journal of Cardiac Failure, 2015, 21, 594-600.	1.7	31
350	Association of 6â€Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. Journal of the American Heart Association, 2015, 4, .	3.7	27
351	Evaluating the Atrial Myopathy Underlying Atrial Fibrillation. Circulation, 2015, 132, 278-291.	1.6	196
352	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation, 2015, 132, 402-414.	1.6	371
353	Left Atrial Decompression Pump forÂSevere Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 275-282.	4.1	67
354	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-Î³) gene and systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 128.	3.5	24
355	Management of Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997.	2.8	296
356	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2015, 373, 2314-2324.	27.0	453
357	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation: Heart Failure, 2015, 8, 1052-1058.	3.9	70
358	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. Current Atherosclerosis Reports, 2015, 17, 64.	4.8	15
359	Association of Chronic Kidney Disease With Chronotropic Incompetence in Heart Failure With Preserved EjectionÂFraction. American Journal of Cardiology, 2015, 116, 1093-1100.	1.6	31
360	A non-invasive assessment of cardiopulmonary hemodynamics with MRI in pulmonary hypertension. Magnetic Resonance Imaging, 2015, 33, 1224-1235.	1.8	15

#	Article	IF	Citations
361	Favorable levels of all major cardiovascular risk factors at younger ages and high-sensitivity C-reactive protein 39years later â€" The Chicago Healthy Aging Study. Preventive Medicine Reports, 2015, 2, 235-240.	1.8	7
362	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	7.4	288
363	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 269-279.	1.6	763
364	Rationale and Design of the Echocardiographic Study of Hispanics/Latinos (ECHO-SOL). Ethnicity and Disease, 2015, 25, 180-6.	2.3	15
365	Rationale and design of the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE</scp> Studies (<scp>SOCRATES</scp>). European Journal of Heart Failure, 2014, 16, 1026-1038.	7.1	119
366	Regulation of Hypoxia-induced Pulmonary Hypertension by Vascular Smooth Muscle Hypoxia-Inducible Factor-1Î±. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 314-324.	5.6	209
367	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 104-115.	3.9	288
368	Albuminuria Is Independently Associated With Cardiac Remodeling, Abnormal Right and Left Ventricular Function, and Worse Outcomes in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 586-596.	4.1	66
369	Association of Comorbidity Burden With Abnormal Cardiac Mechanics: Findings From the HyperGEN Study. Journal of the American Heart Association, 2014, 3, e000631.	3.7	19
370	Diastolic wall strain: a simple marker of abnormal cardiac mechanics. Cardiovascular Ultrasound, 2014, 12, 40.	1.6	14
371	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 740-751.	3.9	218
372	Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 312, 1803.	7.4	11
373	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	1.7	111
374	Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014, 370, 1383-1392.	27.0	1,993
375	Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	4.1	267
376	Association of Low-Grade Albuminuria With Adverse Cardiac Mechanics. Circulation, 2014, 129, 42-50.	1.6	70
377	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Current Cardiology Reports, 2014, 16, 545.	2.9	23
378	Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H88-H100.	3.2	90

#	Article	IF	Citations
379	Association of the Frontal QRS-T Angle with Adverse Cardiac Remodeling, Impaired Left and Right Ventricular Function, and Worse Outcomes in Heart Failure with Preserved Ejection Fraction. Journal of the American Society of Echocardiography, 2014, 27, 74-82.e2.	2.8	29
380	Relationship between repolarization heterogeneity and abnormal myocardial mechanics. International Journal of Cardiology, 2014, 172, 289-291.	1.7	18
381	Electrocardiographic Markers of Repolarization Heterogeneity During Dofetilide or Sotalol Initiation for Paroxysmal Atrial Fibrillation. American Journal of Cardiology, 2014, 113, 2030-2035.	1.6	3
382	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. American Heart Journal, 2014, 167, 853-860.e4.	2.7	128
383	Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal Â± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Diabetes Care, 2014, 37, 372-380.	8.6	16
384	Prognostic Importance of Pathophysiologic Markers in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 288-299.	3.9	166
385	Phenotypic Spectrum of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 407-418.	2.1	126
386	Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 187-195.	3.6	10
387	Vulnerable blood in high risk vascular patients: Study design and methods. Contemporary Clinical Trials, 2014, 38, 121-129.	1.8	11
388	Abstract 15955: Widely Varying Prevalence of Diastolic Dysfunction by Different Classification Criteria: The Cardia Study. Circulation, 2014, 130, .	1.6	1
389	Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons. Current Cardiology Reviews, 2014, 11, 42-52.	1.5	68
390	D-Dimer in the Months Leading up to Acute Coronary Events: A Case Crossover Study. Blood, 2014, 124, 2864-2864.	1.4	0
391	The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2013, 10, 401-410.	3.3	266
392	Relation of Short-Term Heart Rate Variability to Incident Heart Failure (from the Multi-Ethnic Study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	37
393	Matchmaking for the Optimization of Clinical Trials of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 1339-1342.	2.8	80
394	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 123-126.	4.1	8
395	Prevalence, Clinical Characteristics, and Outcomes Associated With Eccentric Versus Concentric Left Ventricular Hypertrophy in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2013, 112, 1158-1164.	1.6	81
396	Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet, The, 2013, 381, 1116-1124.	13.7	129

#	Article	IF	Citations
397	Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H1068-H1079.	3.2	25
398	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 2013, 6, 184-192.	3.9	154
399	Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal of Investigative Dermatology, 2013, 133, 1979-1989.	0.7	150
400	Heart Failure in North America. Current Cardiology Reviews, 2013, 9, 128-146.	1.5	54
401	Diastolic Electromechanical Coupling. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 537-543.	4.8	56
402	Polycystic Ovary Syndrome Is Associated with Higher Left Ventricular Mass Index: The CARDIA Women's Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4656-4662.	3.6	35
403	SERCA2a Gene Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2012, 126, 2047-2050.	1.6	10
404	Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: If You Are Confused, Remember: â€œIt Is a Matter of the Heartâ€• Journal of Rheumatology, 2012, 39, 206-209.	2.0	23
405	Increased Arterial Wave Reflection Magnitude. Journal of the American College of Cardiology, 2012, 60, 2178-2181.	2.8	30
406	Pulmonary Hypertension. JAMA - Journal of the American Medical Association, 2012, 308, 1366.	7.4	70
407	Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 870-876.	1.6	214
408	Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. Journal of Heart and Lung Transplantation, 2012, 31, 467-477.	0.6	41
409	Association of Serum Triiodothyronine With B-Type Natriuretic Peptide and Severe Left Ventricular Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 234-239.	1.6	46
410	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clinical and Experimental Rheumatology, 2012, 30, S30-7.	0.8	49
411	Cardiovascular Risk Assessment of the Liver Transplant Candidate. Journal of the American College of Cardiology, 2011, 58, 223-231.	2.8	223
412	Phase II trials in heart failure: The role of cardiovascular imaging. American Heart Journal, 2011, 162, 3-15.e3.	2.7	13
413	Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. Thrombosis Research, 2011, 128, 422-430.	1.7	49
414	Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet, The, 2011, 378, 498-506.	13.7	446

#	Article	IF	Citations
415	Right Heart Structural Changes Are Independently Associated with Exercise Capacity in Non-Severe COPD. PLoS ONE, 2011, 6, e29069.	2.5	48
416	Systemic sclerosis and the heart. Current Opinion in Rheumatology, 2011, 23, 545-554.	4.3	88
417	Limitations Inherent to the Simplified Bernoulli Equation Explain the Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension: Response. Chest, 2011, 140, 270-271.	0.8	6
418	Usefulness of Electrocardiographic QT Interval to Predict Left Ventricular Diastolic Dysfunction. American Journal of Cardiology, 2011, 108, 1760-1766.	1.6	57
419	Timeâ€resolved magnetic resonance angiography: Evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. Journal of Magnetic Resonance Imaging, 2011, 33, 225-231.	3.4	27
420	Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 257-265.	3.9	253
421	Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension. Chest, 2011, 139, 988-993.	0.8	328
422	MDCT Bolus Tracking Data as an Adjunct for Predicting the Diagnosis of Pulmonary Hypertension and Concomitant Right-Heart Failure. American Journal of Roentgenology, 2011, 197, 1064-1072.	2.2	20
423	Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 58-75.	0.9	27
424	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 181-187.	0.6	62
425	Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure. Journal of Cardiac Failure, 2010, 16, 720-727.	1.7	5
426	Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 226-231.	7.1	280
427	Value of Exercise Treadmill Testing in the Risk Stratification of Patients With Pulmonary Hypertension. Circulation: Heart Failure, 2009, 2, 278-286.	3.9	35
428	Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertensionâ€â€Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Mai. American Journal of Cardiology, 2009, 104, 868-872.	1.6	229
429	Genetics of systemic sclerosis-associated pulmonary arterial hypertension: Recent progress and current concepts. Current Rheumatology Reports, 2009, 11, 89-96.	4.7	5
430	Electrocardiographic Predictors of Abnormal Left Ventricular Diastolic Function: Importance of the QTc Interval. Journal of Cardiac Failure, 2009, 15, S106.	1.7	1
431	Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. American Heart Journal, 2009, 157, 1035-1041.	2.7	124
432	Use of Real Time Three-Dimensional Transesophageal Echocardiography in Intracardiac Catheter Based Interventions. Journal of the American Society of Echocardiography, 2009, 22, 865-882.	2.8	157

#	Article	IF	Citations
433	Prognostic Value of Left Ventricular End-Systolic Volume Index as a Predictor of Heart Failure Hospitalization in Stable Coronary Artery Disease: Data from the Heart and Soul Study. Journal of the American Society of Echocardiography, 2009, 22, 190-197.	2.8	71
434	Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension. Chest, 2009, 136, 694-700.	0.8	42
435	Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2008, 51, 1938-1943.	2.8	87
436	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2008, 300, 431.	7.4	154
437	Association of the Fourth Heart Sound With Increased Left Ventricular End-Diastolic Stiffness. Journal of Cardiac Failure, 2008, 14, 431-436.	1.7	23
438	Physiology of the Third Heart Sound: Novel Insights from Tissue Doppler Imaging. Journal of the American Society of Echocardiography, 2008, 21, 394-400.	2.8	19
439	Real-Time Three-Dimensional Transesophageal Echocardiography of the Left Atrial Appendage: Initial Experience in the Clinical Setting. Journal of the American Society of Echocardiography, 2008, 21, 1362-1368.	2.8	106
440	Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. Circulation, 2008, 117, 2475-2483.	1.6	116
441	Câ€reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. European Journal of Heart Failure, 2008, 10, 63-69.	7.1	62
442	Normalization of Ejection Fraction and Resolution of Symptoms in Chronic Severe Heart Failure is Possible With Modern Medical Therapy: Clinical Observations in 11 Patients. American Journal of Therapeutics, 2008, 15, 206-213.	0.9	11
443	Nesiritide: a reappraisal of efficacy and safety. Expert Opinion on Pharmacotherapy, 2007, 8, 361-369.	1.8	8
444	A distinguishing feature. Journal of Hospital Medicine, 2007, 2, 39-45.	1.4	1
445	Acute Myocardial Infarction in Patients With Versus Without Aortic Valve Sclerosis and Effect of Statin Therapy (from the Heart and Soul Study). American Journal of Cardiology, 2007, 99, 1128-1133.	1.6	29
446	High-Sensitivity C-Reactive Protein and Parameters of Left Ventricular Dysfunction. Journal of Cardiac Failure, 2006, 12, 61-65.	1.7	67
447	Hemodynamic Correlates of the Third Heart Sound and Systolic Time Intervals. Congestive Heart Failure, 2006, 12, 8-13.	2.0	14
448	Hemodynamic Correlates of the Third Heart Sound and Systolic Time Intervals. Congestive Heart Failure, 2006, 12, 8-13.	2.0	24
449	Cystic fibrosis transmembrane conductance regulator in human and mouse red blood cell membranes and its interaction with ecto-apyrase. Journal of Cellular Biochemistry, 2004, 91, 1174-1182.	2.6	27
450	Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. American Journal of Medicine, 2004, 117, 948-952.	1.5	8

#	Article	IF	Citations
451	1H, 13C and 15N NMR assignments and solution secondary structure of rat Apo-S100Î². Journal of Biomolecular NMR, 1995, 6, 171-179.	2.8	45